Empagliflozin 25 mg + Linagliptin 5 mg IR is a combination oral medication used to manage type 2 diabetes mellitus. Empagliflozin, an SGLT2 inhibitor, works by reducing glucose reabsorption in the kidneys, promoting glucose excretion through urine, and thereby lowering blood sugar levels. Linagliptin, a DPP-4 inhibitor, enhances the body’s incretin system to stimulate insulin release and reduce glucagon secretion after meals. Together, this combination helps achieve better glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient. This formulation offers immediate release (IR) action, ensuring rapid onset of therapeutic effect and convenient once-daily dosing. It is suitable for patients who require dual mechanism therapy for improved blood sugar management, while minimizing the risk of hypoglycemia compared to traditional therapies.
